Physician profile
Nicole Kelbon
NPI 1164962510
$6,751.43
in general payments reported to CMS, 2019-2025
21 companies · $420 in 2025
The $420 reported for 2025 was less than what a typical Nuclear Cardiology provider received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,844 · 2021: $579 · 2022: $2,710 · 2023: $660 · 2024: $538 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,521 · Education: $98.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,521.01 |
| Education | $98.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,677.78 | 2020-2024 | Ensite, Assurity, Thoratec Heartmate 3 Lvas Implant Kit |
| Atricure, INC. | $660.33 | 2022-2024 | |
| Boston Scientific Corporation | $525.28 | 2021-2025 | General - Therapies, Watchman Flx |
| Amgen INC. | $326.36 | 2021-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $277.51 | 2022-2025 | Camzyos, Eliquis |
| Pfizer INC. | $194.68 | 2020-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $181.15 | 2023-2025 | Lifevest |
| Medtronic, INC. | $178.33 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $167.73 | 2021-2024 | Farxiga |
| Esperion Therapeutics, INC. | $114.40 | 2021 | |
| Medtronic Vascular, INC. | $105.82 | 2020 | |
| Astellas Pharma US INC | $99.00 | 2021 | |
| Merck Sharp & Dohme LLC | $77.91 | 2022-2023 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $41.63 | 2022 | |
| Edwards Lifesciences Corporation | $20.00 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $19.98 | 2025 | |
| Janssen Pharmaceuticals, INC | $19.67 | 2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.95 | 2023 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $16.85 | 2025 | Uptravi, Opsumit |
| Novo Nordisk INC | $16.47 | 2025 | Wegovy |
| Irhythm Technologies, INC. | $13.60 | 2023 | Zio Xt Patch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Kelbon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.